Precision Medicine in Bariatric Procedures

K Gala, W Ghusn, A Acosta - Gastrointestinal Endoscopy …, 2024 - giendo.theclinics.com
The prevalence of obesity in the United States is greater than 40% currently and is estimated
to reach nearly 50% by 2030. 1, 2 This enormous burden of the disease leads to a heavy …

Type-2 diabetes mellitus remission prediction models after Roux-En-Y gastric bypass and sleeve gastrectomy based on disease severity scores

W Ghusn, K Hage, RA Vierkant… - Diabetes Research and …, 2024 - Elsevier
Aim Metabolic and bariatric surgery (MBS) is considered one of the most effective
interventions for weight loss and associated type-2 diabetes mellitus (T2DM) remission …

[HTML][HTML] Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity

W Ghusn, G Calderon, BKA Dayyeh… - Clinical …, 2024 - pmc.ncbi.nlm.nih.gov
Endoscopic bariatric therapies (EBTs) are minimally invasive and safe procedures with
favorable weight loss outcomes in obesity treatment. We aimed to present the weight loss …

Cumulative effect of obesity phenotypes on body weight and body mass index

W Ghusn, L Cifuentes, D Anazco, S Fansa… - International Journal of …, 2024 - nature.com
Background Obesity originates from an imbalance between energy intake and expenditure.
Changes in energy intake components (satiation, postprandial satiety, emotional eating) and …

The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes

W Ghusn, S Fansa, D Anazco, E Tama… - Diabetes, Obesity …, 2024 - Wiley Online Library
Aims To compare weight loss outcomes between patients starting semaglutide who had
previously been on another anti‐obesity medication (AOM) compared to those who were …